Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
The Associated Press - July 19, 1999
Joann Loviglio
The study published in this week's Annals of Internal Medicine looked at 273 patients infected with HIV-1, the most common type of the virus, who received a powerful multidrug regimen as outpatients at the Johns Hopkins HIV Clinic in Baltimore between March 1996 and February 1998.
The researchers compared the progress of those patients with the results for patients in clinical trials.
Both groups were treated with highly active antiretroviral therapy, or HAART - more commonly known as combination or "cocktail" therapy - which has produced dramatic reductions in mortality rates associated with HIV infection in the United States since its introduction in 1996.
According to the study, 37 percent of the Johns Hopkins patients getting the cocktail treatment had undetectable HIV levels one year after starting therapy. Only 23 percent suppressed the virus in all three time periods studied - 1-90 days, 3-7 months and 7-14 months.
Clinical trials using similar drugs show suppression rates twice as high as those numbers.
The cocktail, a mixture of protease inhibitors and other anti-HIV drugs, can inhibit HIV's ability to replicate, causing the virus to plummet to undetectable levels.
But the therapy must be precisely followed to successfully combat HIV, the virus that causes AIDS. That's not always easy. Patients have to take lots of pills and adhere to complicated dosing schedules. The drugs also may cause side effects.
According to the study, missed clinic visits were the strongest independent risk factor that prevented patients from reducing their body's HIV levels as low as those in more strictly monitored clinical trials. Poorer outcomes were also found among non-Caucasian groups and people above age 40.
One physician said the findings mirror what some doctors have been seeing in their own experiences but questioned whether study's comparison of two very different groups was valid.
"Patients who tend to participate in clinical studies tend to be more self-motivated to begin with," said Dr. Ian Frank, director of antiretroviral clinical research at the University of Pennsylvania.
"And patients less likely to adhere to a complex pill-taking regimen are generally not admitted to clinical studies."
The study was conducted by three doctors at the Johns Hopkins University School of Medicine. They were not available for comment Monday.
990719
AP990711
Copyright © 1999 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, Pacific Life Foundation, and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .